What AI Driven Imaging Data Analysis Could Mean for Bio-Pharmaceutical R&D?

What AI Driven Imaging Data Analysis Could Mean for Bio-Pharmaceutical R&D?

Dr Olga Kubassova, Scientific Founder and CEO of IAG, Image Analysis Group is invited to speak at the 6th Annual – Life Science, R&D Data Intelligence Leaders Forum, January 23-25, 2019, Basel, Switzerland.

Olga is a mathematician with expertise in actively managing innovation in life science companies, asset positioning, strategy and bio-pharma investment. Her expertise and domain knowledge are in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics.

In this talk, she will cover topics critical to successful bio-pharmaceutical drug development and early go / no go decision support:

  • What AI Driven Imaging Data Analysis Could Mean for Bio-Pharmaceutical R&D?
  • How AI and Machine Learning are Changing our Approach to the Assessment of Trial Outcomes?
  • Getting AI into your R&D is Simple and Necessary

AI driven insights are very different from the traditional analytics as they are much more data intensive and detailed. With the rise of novel technologies, we have an opportunity to bring the power of machine learning and decision support to make objective, accurate and early decisions, especially at early stages of clinical development.


About Next Level Life Sciences

NextLevel Life Sciences is a leading, strategic business information provider and opportunity facilitator for the international life sciences industry. This event serves as a platform where senior executives, leading experts and key stakeholders meet together to share ideas, achieve critical insights and discover practical solutions to enhance medical innovation for patient benefit. To find out more about this conference click here.

About IAG

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com